|
|
"Comparative gene resequencing in mouse cancer models"
|
5K08CA160658-02
|
$180,360
|
$90,180
|
McFadden, David
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
|
"Target Specific and Drug Loaded Iron Oxide Nanoparticles for Cancer Imaging and
|
N44CO120029-000
|
$1,200,000
|
$1,200,000
|
WANG, ANDREW
|
OCEAN NANO TECH LLC
|
|
|
11th International Conference on Cancer-Induced Bone Disease in Chicago, IL, in p
|
1R13CA165751-01
|
$3,000
|
$3,000
|
Baliozian, Kevin
|
INTERNATIONAL BONE AND MINERAL SOCIETY
|
|
|
124I-cG250 ImmunoPET Imaging of Sunitinib Treatment Response in Renal Cell Cancer
|
5R21CA162602-02
|
$379,518
|
$379,518
|
Larson, Steven
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
|
15-Lipoxygenase-2 (ALOX15B) as a Tumor Suppressor
|
5R01CA131445-05
|
$214,879
|
$214,879
|
NIE, DAOTAI
|
SOUTHERN ILLINOIS UNIVERSITY SCH OF MED
|
|
|
2010 Mammary Gland Biology GRC
|
5R13CA150225-03
|
$5,000
|
$2,500
|
JERRY, D
|
GORDON RESEARCH CONFERENCES
|
|
|
3D-Adhesion Stromagenesis in Cancer Permissiveness
|
2R01CA113451-06A1
|
$245,775
|
$245,775
|
CUKIERMAN, EDNA
|
INSTITUTE FOR CANCER RESEARCH
|
|
|
A 3-D in vitro platform of tumor metastasis (PQ24)
|
1R01CA170879-01
|
$338,175
|
$338,175
|
GEORGE, STEVEN
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
|
A Cellular and Molecular Analysis of the Intravasation Step in Tumor Metastasis
|
5R01CA129484-05
|
$381,417
|
$381,417
|
QUIGLEY, JAMES
|
SCRIPPS RESEARCH INSTITUTE
|
|
|
A Genetic Screen for HCC Genes
|
5R01CA132962-03
|
$302,919
|
$302,919
|
LARGAESPADA, DAVID
|
UNIVERSITY OF MINNESOTA
|
|
|
A Hypersensitive ER alpha Mutant in Breast Cancer Hormone Resistance
|
3R01CA072038-15S1
|
$49,685
|
$16,396
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A Hypersensitive ER alpha Mutant in Breast Cancer Hormone Resistance
|
5R01CA072038-15
|
$291,192
|
$96,093
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A Mitogen-induced G Protein-coupled Receptor
|
ZIASC009389
|
$123,443
|
$123,443
|
Kelly, Kathleen
|
CCR (NCI)
|
|
|
A novel combination therapy for the treatment of Pancreatic adenocarcinoma
|
5R03CA149857-02
|
$74,250
|
$37,125
|
HOLLINGSWORTH, MICHAEL
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
|
A Novel Dose Calculation Method for Targeted Radionuclide Therapy
|
7R01CA138986-03
|
$327,806
|
$163,903
|
MOURTADA, FIRAS
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
|
A novel function of TIMP-1
|
5R01CA089113-10
|
$261,358
|
$65,340
|
KIM, HYEONG-REH
|
WAYNE STATE UNIVERSITY
|
|
|
A novel growth regulatory factor in breast cells
|
5R01CA092440-10
|
$290,758
|
$72,690
|
MONTANO, MONICA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
A Novel Lineage Specific Metastasis Suppressor Pathway in Lung Cancer
|
1R01CA166376-01A1
|
$385,406
|
$385,406
|
Nguyen, Don
|
YALE UNIVERSITY
|
|
|
A novel murine model for metastatic islet cell pancreas cancer
|
1R21CA164795-01
|
$219,599
|
$219,599
|
GROSS, KENNETH
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
|
A Novel Plasminogen Receptor in Breast Cancer
|
1R01CA166473-01
|
$464,971
|
$464,971
|
MUELLER, BARBARA
|
TORREY PINES INST FOR MOLECULAR STUDIES
|
|
|
A novel preclinical model of spontaneous metastasis
|
ZIABC011167
|
$290,312
|
$203,219
|
Merlino, Glenn
|
CCR (NCI)
|
|
|
A Novel Therapeutic Approach for Primary and Metastatic Prostate Cancer
|
5R01CA150182-02
|
$293,483
|
$293,483
|
AHMED, KHALIL
|
UNIVERSITY OF MINNESOTA
|
|
|
A Pathway of Tumor Suppression
|
2R01CA047296-24
|
$249,580
|
$62,395
|
Lozano, Guillermina
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
A program of immune-based treatments for cancer
|
5K24CA093670-10
|
$182,272
|
$45,568
|
CARSON, WILLIAM
|
OHIO STATE UNIVERSITY
|
|
|
A Risk Prediction Model for Colorectal Cancer Screening
|
5R01CA131197-05
|
$430,622
|
$430,622
|
SCHROY, PAUL
|
BOSTON MEDICAL CENTER
|
|
|
A role for c-Abl/Arg in melanoma progression
|
1R01CA166499-01A1
|
$315,543
|
$315,543
|
PLATTNER, RINA
|
UNIVERSITY OF KENTUCKY
|
|
|
A Role for Fatty Acid Binding Protein 4 in Ovarian Cancer Metastasis
|
1F32CA168309-01
|
$53,942
|
$53,942
|
Nieman, Kristin
|
UNIVERSITY OF CHICAGO
|
|
|
A Role of Novel Serpin Maspinin Prostate Tumor/Bone Interaction
|
5R01CA127735-05
|
$302,919
|
$302,919
|
SHENG, SHIJIE
|
WAYNE STATE UNIVERSITY
|
|
|
A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors
|
1R41CA174031-01
|
$266,641
|
$266,641
|
Jones, Barry
|
ARISAPH PHARMACEUTICALS, INC.
|
|
|
A Systems Approach To Iron Metabolism In Cancer Cells
|
5R21CA156133-02
|
$201,615
|
$201,615
|
LAUBENBACHER, REINHARD
|
VIRGINIA POLYTECHNIC INST AND ST UNIV
|
|
|
A Systems Genetics Analysis of Cancer Risk, Progression and Therapeutic Response
|
5U01CA084244-14
|
$759,738
|
$75,974
|
BALMAIN, ALLAN
|
UNIVERSITY OF CALIFORNIA-SAN FRANCISCO
|
|
|
A Viral Cytokine as a Promoter of Tumor Progression
|
3R15CA158767-01S1
|
$79,902
|
$39,951
|
SPENCER, JULIET
|
UNIVERSITY OF SAN FRANCISCO
|
|
|
A10Tg mice, a model of MDSC development and function in a tumor free environment
|
5F31CA159877-02
|
$33,310
|
$33,310
|
Saleem, Sheinei
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-36
|
$7,725,062
|
$772,506
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer
|
5R01CA135328-03
|
$328,495
|
$328,495
|
Mahajan, Nupam
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
|
Ack1: Activation and Consequences in Prostate Cancer
|
5R01CA120304-04
|
$296,195
|
$296,195
|
EARP, HENRY
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
|
|
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity
|
5P01CA128913-05
|
$1,898,043
|
$341,648
|
HWU, PATRICK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
ACTIVIN SIGNALING AND REGULATION IN THE COLON
|
5R01CA141057-03
|
$276,251
|
$138,126
|
JUNG, BARBARA
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
|
ADAM17 in pancreatic cancer and pancreatitis
|
7R01CA159222-02
|
$390,135
|
$390,135
|
CRAWFORD, HOWARD
|
MAYO CLINIC JACKSONVILLE
|
|
|
Adenosine in Tumor-Host Interaction
|
5R01CA138923-03
|
$353,239
|
$88,310
|
DIKOV, MIKHAIL
|
VANDERBILT UNIVERSITY MED CTR
|
|
|
Adhesive regulation during cell migration
|
5R01CA085862-13
|
$278,257
|
$278,257
|
HUTTENLOCHER, ANNA
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
|
Adiposity and Outcomes of Clinically Localized Prostate Cancer
|
5R01CA129140-04
|
$569,690
|
$569,690
|
Freeman, Vincent
|
UNIVERSITY OF ILLINOIS
|
|
|
Adoption and Retooling of GEM model for Pancreatic Cancer
|
ZIABC011463
|
$148,216
|
$74,108
|
Van Dyke, Terry
|
CCR (NCI)
|
|
|
Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide
|
5R01CA134844-04
|
$312,186
|
$312,186
|
MITCHELL, DUANE
|
DUKE UNIVERSITY
|
|
|
Adoptive T cell Therapy of Melanoma Targeting NY-ESO-1
|
5R01CA104711-08
|
$373,963
|
$373,963
|
YEE, CASSIAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Adrenergic regulation of tumor inflammation and metastatic dissemination
|
1R01CA160890-01A1
|
$319,550
|
$319,550
|
Sloan, Erica
|
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
|
|
|
Advanced Development of An Integrated CTC Enrichment Technology
|
5R33CA157396-02
|
$228,724
|
$114,362
|
TSENG, HSIAN-RONG
|
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
|
|
|
Advanced Ultrasonic Evaluation of Sentinel Lymph Nodes
|
5R01CA100183-06
|
$241,652
|
$241,652
|
Feleppa, Ernest
|
RIVERSIDE RESEARCH INSTITUTE
|
|
|
AEG-1: Novel Gene Involved in Malignant Glioma
|
5R01CA134721-04
|
$300,907
|
$300,907
|
FISHER, PAUL
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
|
AFAP-110 as a cSrc activator in breast cancer
|
5R01CA060731-18
|
$227,829
|
$227,829
|
HOLT, JEFFREY
|
COMMONWEALTH MEDICAL COLLEGE
|
|
Total relevant funding to Metastasis for this search: $396,456,505
|
